Company profile

Cheplapharm Arzneimittel GmbH

acquired/legacy branded pharmaceuticals (specialty licensing and commercialization)

Privately held: no public share price · Greifswald, Germany

Assets

(5 total)
5Total Assets
5Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Capecitabine
Approved
Fluoropyrimidine (antimetabolite)Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Olanzapine (Zyprexa Relprevv)(Zyprexa Relprevv)
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Olanzapine (Zyprexa)(Zyprexa)
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Quetiapine (Seroquel XR)(Seroquel XR)
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Quetiapine (Seroquel)(Seroquel)
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.